688046 药康生物
已收盘 11-15 15:00:00
资讯
新帖
简况
药康生物11月14日遭主力抛售882万元 环比增加361.78%
市场透视 · 11-14 15:20
药康生物11月14日遭主力抛售882万元 环比增加361.78%
药康生物11月12日主力资金流出437万元 连续3日减仓
市场透视 · 11-12
药康生物11月12日主力资金流出437万元 连续3日减仓
药康生物:拟回购2000万元-4000万元股份
美港电讯 · 11-07
药康生物:拟回购2000万元-4000万元股份
国元证券:给予药康生物买入评级
证券之星 · 11-07
国元证券:给予药康生物买入评级
药康生物2024年三季度报告点评:扩张期成本增加及政府补助减少使得利润短期承压
国元证券 · 11-07
药康生物2024年三季度报告点评:扩张期成本增加及政府补助减少使得利润短期承压
药康生物11月06日主力资金流出1270万元 连续3日减仓
市场透视 · 11-06
药康生物11月06日主力资金流出1270万元 连续3日减仓
华安证券:给予药康生物买入评级
证券之星 · 11-05
华安证券:给予药康生物买入评级
华安证券给予药康生物买入评级,收入稳步增长,费用投放加大等因素致利润承压
每日经济新闻 · 11-05
华安证券给予药康生物买入评级,收入稳步增长,费用投放加大等因素致利润承压
药康生物:10月31日接受机构调研,包括知名机构聚鸣投资的多家机构参与
证券之星 · 11-04
药康生物:10月31日接受机构调研,包括知名机构聚鸣投资的多家机构参与
开源证券:给予药康生物买入评级
证券之星 · 11-03
开源证券:给予药康生物买入评级
药康生物(688046)9月30日股东户数0.65万户,较上期减少13.77%
证券之星 · 10-31
药康生物(688046)9月30日股东户数0.65万户,较上期减少13.77%
药康生物大跌5.04% 5家券商给予增持建议
智选洞察 · 10-31
药康生物大跌5.04% 5家券商给予增持建议
图解药康生物三季报:第三季度单季净利润同比减45.51%
证券之星 · 10-31
图解药康生物三季报:第三季度单季净利润同比减45.51%
药康生物:营收稳健增长 利润端短期承压
国信证券 · 10-31
药康生物:营收稳健增长 利润端短期承压
药康生物拟以2200万元至4000万元回购公司股份
北京商报 · 10-30
药康生物拟以2200万元至4000万元回购公司股份
药康生物大跌5.15% 6家券商给予增持建议
智选洞察 · 10-29
药康生物大跌5.15% 6家券商给予增持建议
药康生物大幅上涨 四川深化医疗服务价格改革试点实施方案印发
智选洞察 · 10-25
药康生物大幅上涨 四川深化医疗服务价格改革试点实施方案印发
药康生物10月21日主力资金流入182万元 连续3日加仓
市场透视 · 10-21
药康生物10月21日主力资金流入182万元 连续3日加仓
药康生物:业绩说明会定于10月22日举行
每日经济新闻 · 10-14
药康生物:业绩说明会定于10月22日举行
药康生物大跌5.06% 8家券商给予增持建议
智选洞察 · 10-14
药康生物大跌5.06% 8家券商给予增持建议
加载更多
公司概况
公司名称:
江苏集萃药康生物科技股份有限公司
所属行业:
研究和试验发展
上市日期:
2022-04-25
主营业务:
江苏集萃药康生物科技股份有限公司是一家专业从事实验动物小鼠模型的研发、生产、销售及相关技术服务的高新技术企业,主要产品有商品化小鼠模型销售业务、模型定制业务、定制繁育业务、功能药效业务、代理进出口及其他业务。公司为国内模式动物行业龙头企业之一,是亚洲小鼠突变和资源联盟唯一企业成员、国家科技资源共享服务平台(国家遗传工程小鼠资源库)共建单位,先后被认定为国家级高新技术企业、江苏省博士后创新实践基地、江苏省工程技术研究中心、国家级专精特新小巨人企业等。
发行价格:
22.53
{"stockData":{"symbol":"688046","market":"SH","secType":"STK","nameCN":"药康生物","latestPrice":13.42,"timestamp":1731654000000,"preClose":13.7,"halted":0,"volume":3932485,"delay":0,"floatShares":204000000,"shares":409999999,"eps":0.3401,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.28,"latestTime":"11-15 15:00:00","open":13.65,"high":13.92,"low":13.37,"amount":54007000,"amplitude":0.0401,"askPrice":13.43,"askSize":54,"bidPrice":13.42,"bidSize":25,"shortable":0,"etf":0,"ttmEps":0.3401,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731893400000},"adr":0,"adjPreClose":13.7,"symbolType":"stock_kcb","openAndCloseTimeList":[[1731634200000,1731641400000],[1731646800000,1731654000000]],"highLimit":15.07,"lowLimit":12.33,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":410000000,"pbRate":2.59,"roa":"--","roe":"4.61%","epsLYR":0.39,"committee":-0.156214,"marketValue":5502000000,"floatMarketCap":2737000000,"peRate":39.458984,"changeRate":-0.0204,"turnoverRate":0.0193,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-11-18。","afterMarket":{"amount":0,"volume":0,"close":13.42,"buyVolume":0,"sellVolume":0,"time":1731656039464,"indexStatus":"已收盘 11-15 15:30:00","preClose":13.7}},"requestUrl":"/m/hq/s/688046","defaultTab":"news","newsList":[{"id":"2483634846","title":"药康生物11月14日遭主力抛售882万元 环比增加361.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483634846","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483634846?lang=zh_cn&edition=full","pubTime":"2024-11-14 15:20","pubTimestamp":1731568836,"startTime":"0","endTime":"0","summary":"11月14日, 药康生物股价跌4.53%,报收13.70元,成交金额7836万元,换手率2.75%,振幅4.81%,量比0.88。药康生物今日主力资金净流出882万元,连续5日净流出,上一交易日主力净流出191万元,今日环比增加361.78%。近一年数据显示,该股主力连续5日净流出后,次日下跌概率为37.50%,平均跌幅为4.70%。该股近5个交易日下跌4.06%,主力资金累计净流出3549万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流出5927万元,其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114154118a2369501&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114154118a2369501&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688046"],"gpt_icon":0},{"id":"2482726053","title":"药康生物11月12日主力资金流出437万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2482726053","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482726053?lang=zh_cn&edition=full","pubTime":"2024-11-12 15:21","pubTimestamp":1731396074,"startTime":"0","endTime":"0","summary":"11月12日, 药康生物股价跌1.01%,报收14.77元,成交金额1.08亿元,换手率3.55%,振幅5.09%,量比1.06。药康生物今日主力资金净流出437万元,连续3日净流出,上一交易日主力净流出705万元,今日环比减少38.01%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为58.82%,平均跌幅为1.74%。该股近5个交易日上涨5.50%,主力资金累计净流出3411万元;近20日主力资金累计净流出5091万元,其中净流出天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112154806a22f8620&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112154806a22f8620&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688046","BK0216"],"gpt_icon":0},{"id":"2481924898","title":"药康生物:拟回购2000万元-4000万元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2481924898","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481924898?lang=zh_cn&edition=full","pubTime":"2024-11-07 16:54","pubTimestamp":1730969692,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["688046","BK0216"],"gpt_icon":0},{"id":"2481213945","title":"国元证券:给予药康生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2481213945","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481213945?lang=zh_cn&edition=full","pubTime":"2024-11-07 14:01","pubTimestamp":1730959275,"startTime":"0","endTime":"0","summary":"国元证券股份有限公司马云涛,朱仕平近期对药康生物进行研究并发布了研究报告《2024年三季度报告点评:扩张期成本增加及政府补助减少使得利润短期承压》,本报告对药康生物给出买入评级,当前股价为14.26元。维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有7家机构给出评级,买入评级3家,增持评级4家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110700019208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","000728"],"gpt_icon":0},{"id":"2481948040","title":"药康生物2024年三季度报告点评:扩张期成本增加及政府补助减少使得利润短期承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2481948040","media":"国元证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481948040?lang=zh_cn&edition=full","pubTime":"2024-11-07 00:00","pubTimestamp":1730908800,"startTime":"0","endTime":"0","summary":"事件药康生物于近日发布2024 年三季度报告:2024 年前三季度公司实现收入5.1 亿元,实现归母净利润9821.4 万元、扣非归母净利润7181.0 万元。利润下降主要系公司目前仍处扩张期,生产规模扩大成本增加,持续加大海外市场开发力度销售费用上涨等原因,使公司利润短期承压;同时本年度取得政府补助金额较上年同期减少。维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110713412295bde2fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110713412295bde2fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688046","BK0216"],"gpt_icon":0},{"id":"2481640365","title":"药康生物11月06日主力资金流出1270万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2481640365","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481640365?lang=zh_cn&edition=full","pubTime":"2024-11-06 15:19","pubTimestamp":1730877558,"startTime":"0","endTime":"0","summary":"11月06日, 药康生物股价跌1.57%,报收13.78元,成交金额1.03亿元,换手率3.67%,振幅3.79%,量比1.17。药康生物今日主力资金净流出1270万元,连续3日净流出,上一交易日主力净流出1360万元,今日环比减少6.62%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为56.25%,平均跌幅为1.90%。该股近5个交易日上涨0.80%,主力资金累计净流出3728万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出2659万元,其中净流出天数为10日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106153854aba5340c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106153854aba5340c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688046","BK0216"],"gpt_icon":0},{"id":"2481930965","title":"华安证券:给予药康生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2481930965","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481930965?lang=zh_cn&edition=full","pubTime":"2024-11-05 08:45","pubTimestamp":1730767519,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超近期对药康生物进行研究并发布了研究报告《收入稳步增长,费用投放加大等因素致利润承压》,本报告对药康生物给出买入评级,当前股价为13.35元。维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有6家机构给出评级,买入评级2家,增持评级4家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500007331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","600909"],"gpt_icon":0},{"id":"2481759365","title":"华安证券给予药康生物买入评级,收入稳步增长,费用投放加大等因素致利润承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2481759365","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481759365?lang=zh_cn&edition=full","pubTime":"2024-11-05 08:44","pubTimestamp":1730767490,"startTime":"0","endTime":"0","summary":"华安证券11月04日发布研报称,给予药康生物(688046.SH,最新价:13.35元)买入评级。评级理由主要包括:1)收入端稳健增长,费用投放加大等因素影响利润表现;2)海外市场积极拓展,产能利用率稳步提升。风险提示:基因编辑通用技术升级迭代风险;实验动物管理风险;新产品动物模型研发风险;市场放量不及预期风险;工业端恢复不及预期风险。AI点评:药康生物近一个月获得2份券商研报关注,买入1家。文章来源:每日经济新闻原标题:华安证券给予药康生物买入评级,收入稳步增长,费用投放加大等因素致利润承压","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105084912a2164120&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105084912a2164120&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688046","600909"],"gpt_icon":0},{"id":"2480583783","title":"药康生物:10月31日接受机构调研,包括知名机构聚鸣投资的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2480583783","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480583783?lang=zh_cn&edition=full","pubTime":"2024-11-04 21:35","pubTimestamp":1730727326,"startTime":"0","endTime":"0","summary":"Q3 海外市场拓展顺利,新客户数量持续增长,同时在非核心区域,增加和代理商合作,提高市场渗透率。公司本年度战略入股灵康生物,将业务拓展至实验猪领域。答:公司目前库存股约 150 万股,并于近期公告了新的股份购计划,适时会推出股权激励或员工持股计划。该股最近90天内共有6家机构给出评级,买入评级2家,增持评级4家。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400031439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"gpt_icon":0},{"id":"2480365035","title":"开源证券:给予药康生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480365035","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480365035?lang=zh_cn&edition=full","pubTime":"2024-11-03 20:46","pubTimestamp":1730637982,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,汪晋近期对药康生物进行研究并发布了研究报告《公司信息更新报告:前三季度营收稳健增长,多因素影响利润阶段性承压》,本报告对药康生物给出买入评级,当前股价为13.12元。最新盈利预测明细如下:该股最近90天内共有6家机构给出评级,买入评级2家,增持评级4家。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110300001814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","161027"],"gpt_icon":0},{"id":"2479745927","title":"药康生物(688046)9月30日股东户数0.65万户,较上期减少13.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479745927","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479745927?lang=zh_cn&edition=full","pubTime":"2024-10-31 17:10","pubTimestamp":1730365826,"startTime":"0","endTime":"0","summary":"证券之星消息,近日药康生物披露,截至2024年9月30日公司股东户数为6479.0户,较6月30日减少1035.0户,减幅为13.77%。在医疗服务行业个股中,药康生物股东户数低于行业平均水平,截至9月30日,医疗服务行业平均股东户数为4.51万户。从股价来看,2024年6月30日至2024年9月30日,药康生物区间涨幅为46.72%,在此期间股东户数减少1035.0户,减幅为13.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100033737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"gpt_icon":0},{"id":"2479716357","title":"药康生物大跌5.04% 5家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2479716357","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479716357?lang=zh_cn&edition=full","pubTime":"2024-10-31 09:58","pubTimestamp":1730339910,"startTime":"0","endTime":"0","summary":"10月31日,药康生物股价大幅下跌,截至09点58分,药康生物下跌5.04%,报13.01元/股,成交3489万元,换手率1.29%,振幅3.72%。此外,数据统计显示,近半年内5家券商给予增持建议,5家券商给予买入建议。资金动向截止发稿,药康生物获得主力净流出738万元,其中超大单流出408万元,大单流出329万元。最新财报显示,今年三季报,药康生物实现营业收入5.10亿元,同比增长12.13%,净利润为9,821.44万元,同比减少16.57%,基本每股收益为0.24元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031095836ab87a557&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031095836ab87a557&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688046","BK0216"],"gpt_icon":0},{"id":"2479753906","title":"图解药康生物三季报:第三季度单季净利润同比减45.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479753906","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479753906?lang=zh_cn&edition=full","pubTime":"2024-10-31 02:01","pubTimestamp":1730311318,"startTime":"0","endTime":"0","summary":"证券之星消息,药康生物2024年三季报显示,公司主营收入5.1亿元,同比上升12.13%;归母净利润9821.44万元,同比下降16.57%;扣非净利润7181.03万元,同比下降12.06%;其中2024年第三季度,公司单季度主营收入1.69亿元,同比上升6.7%;单季度归母净利润2187.67万元,同比下降45.51%;单季度扣非净利润1697.33万元,同比下降47.17%;负债率16.19%,投资收益763.88万元,财务费用-627.0万元,毛利率63.65%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100003105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046"],"gpt_icon":0},{"id":"2479703486","title":"药康生物:营收稳健增长 利润端短期承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2479703486","media":"国信证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479703486?lang=zh_cn&edition=full","pubTime":"2024-10-31 00:00","pubTimestamp":1730304000,"startTime":"0","endTime":"0","summary":"营收稳健增长,利润端短期承压。2024Q1-3,公司实现营收5.10 亿元,预计主要系随着国内新产能释放及海外市场拓展,各业务条线均稳健增长;归母净利润9821 万元,扣非归母净利润7181万元,预计主要系公司目前仍处扩张期,生产规模扩大成本增加,持续加大海外市场开发力度,销售费用上涨等原因,使公司利润短期承压,同时本年度取得政府补助金额较上年同期减少,导致利润下降。毛/净利率承压,研发费用率改善。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410311815429f58f0f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410311815429f58f0f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688046"],"gpt_icon":0},{"id":"2479780997","title":"药康生物拟以2200万元至4000万元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2479780997","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479780997?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:14","pubTimestamp":1730294060,"startTime":"0","endTime":"0","summary":"北京商报讯(记者丁宁)10月30日晚间,药康生物(688046)发布公告称,公司拟通过集中竞价交易方式回购部分公司已发行的人民币普通股(A股)股票,回购股份金额不低于2200万元(含),不超过4000万元(含)。公告显示,回购股份资金来源为公司自有资金和股票回购专项贷款资金(包括兴业银行股份有限公司南京建邺支行提供的股票回购专项贷款)。回购股份用途为员工持股计划或股权激励。文章来源:北京商报原标题:药康生物拟以2200万元至4000万元回购公司股份","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030231015ab84c123&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030231015ab84c123&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688046","BK0216"],"gpt_icon":0},{"id":"2479449046","title":"药康生物大跌5.15% 6家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2479449046","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479449046?lang=zh_cn&edition=full","pubTime":"2024-10-29 14:12","pubTimestamp":1730182328,"startTime":"0","endTime":"0","summary":"10月29日,药康生物股价大幅下跌,截至14点12分,药康生物下跌5.15%,报13.62元/股,成交9158万元,换手率3.21%。此外,数据统计显示,近半年内6家券商给予增持建议,6家券商给予买入建议。资金动向截止发稿,药康生物获得主力净流出656万元,其中超大单流出509万元,大单流出145万元。最新财报显示,今年中报,药康生物实现营业收入3.40亿元,同比增长15.05%,净利润为7,633.77万元,同比减少1.59%,基本每股收益为0.19元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029141241ab7daff2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029141241ab7daff2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688046","BK0216"],"gpt_icon":0},{"id":"2478641803","title":"药康生物大幅上涨 四川深化医疗服务价格改革试点实施方案印发","url":"https://stock-news.laohu8.com/highlight/detail?id=2478641803","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478641803?lang=zh_cn&edition=full","pubTime":"2024-10-25 10:31","pubTimestamp":1729823512,"startTime":"0","endTime":"0","summary":"10月25日,药康生物股价大幅上涨,截至10点31分,药康生物上涨5.02%,报13.61元/股,成交6177万元,换手率2.30%,振幅6.17%。今年3月,四川被国家医保局确定为深化医疗服务价格改革试点省份。资金动向截止发稿,药康生物获得主力净流出806万元,其中超大单流出892万元,大单流入87万元。主营业务及业绩药康生物公司主营业务为实验动物小鼠模型的研发、生产、销售及相关技术服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025103530a1e892d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025103530a1e892d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688046","BK0216"],"gpt_icon":0},{"id":"2477588479","title":"药康生物10月21日主力资金流入182万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2477588479","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477588479?lang=zh_cn&edition=full","pubTime":"2024-10-21 15:18","pubTimestamp":1729495115,"startTime":"0","endTime":"0","summary":"10月21日, 药康生物股价涨2.07%,报收12.83元,成交金额1.06亿元,换手率4.07%,振幅3.50%,量比1.14。药康生物今日主力资金净流入182万元,连续3日净流入,上一交易日主力净流入332万元,今日环比减少45.18%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为41.67%,平均涨幅为5.08%。该股近5个交易日下跌0.93%,主力资金累计净流出36万元;近20日主力资金累计净流入1979万元,其中净流入天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102115295995b7ff7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102115295995b7ff7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688046","BK0216"],"gpt_icon":0},{"id":"2475334490","title":"药康生物:业绩说明会定于10月22日举行","url":"https://stock-news.laohu8.com/highlight/detail?id=2475334490","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475334490?lang=zh_cn&edition=full","pubTime":"2024-10-14 16:08","pubTimestamp":1728893307,"startTime":"0","endTime":"0","summary":"每经AI快讯,药康生物 10月14日晚间发布公告称,公司2024年半年度业绩说明会定于2024年10月22日下午16:00-17:00,以上证路演中心网络互动的形式进行。出席本次业绩说明会的人员有:总经理赵静,董事会秘书王逸鸥,财务总监徐崇博独立,董事余波。2023年1至12月份,药康生物的营业收入构成为:科学研究和技术服务占比99.93%。截至发稿,药康生物市值为53亿元。道达号“个股趋势”提醒:1. 近30日内无机构对药康生物进行调研。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101416085395a6526f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101416085395a6526f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688046"],"gpt_icon":0},{"id":"2475809093","title":"药康生物大跌5.06% 8家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2475809093","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475809093?lang=zh_cn&edition=full","pubTime":"2024-10-14 10:05","pubTimestamp":1728871558,"startTime":"0","endTime":"0","summary":"10月14日,药康生物股价大幅下跌,截至10点05分,药康生物下跌5.06%,报12.56元/股,成交3038万元,换手率1.15%,振幅7.86%。此外,数据统计显示,近半年内8家券商给予增持建议,8家券商给予买入建议。资金动向截止发稿,药康生物获得主力净流出165万元,其中超大单流出65万元,大单流出99万元。最新财报显示,今年中报,药康生物实现营业收入3.40亿元,同比增长15.05%,净利润为7,633.77万元,同比减少1.59%,基本每股收益为0.19元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241014100609ab69d3e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241014100609ab69d3e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688046"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-04-25","address":"江苏省南京市浦口区江北新区学府路12号","stockEarnings":[{"period":"1week","weight":-0.0635},{"period":"1month","weight":0.1107},{"period":"3month","weight":0.2984},{"period":"6month","weight":0.1705},{"period":"1year","weight":-0.2861},{"period":"ytd","weight":-0.3232}],"companyName":"江苏集萃药康生物科技股份有限公司","boardCode":"AI0073","perCapita":"31475股","boardName":"研究和试验发展","registeredCapital":"41000万元","compareEarnings":[{"period":"1week","weight":-0.0352},{"period":"1month","weight":0.0399},{"period":"3month","weight":0.1567},{"period":"6month","weight":0.056},{"period":"1year","weight":0.0917},{"period":"ytd","weight":0.1196}],"survey":" 江苏集萃药康生物科技股份有限公司是一家专业从事实验动物小鼠模型的研发、生产、销售及相关技术服务的高新技术企业,主要产品有商品化小鼠模型销售业务、模型定制业务、定制繁育业务、功能药效业务、代理进出口及其他业务。公司为国内模式动物行业龙头企业之一,是亚洲小鼠突变和资源联盟唯一企业成员、国家科技资源共享服务平台(国家遗传工程小鼠资源库)共建单位,先后被认定为国家级高新技术企业、江苏省博士后创新实践基地、江苏省工程技术研究中心、国家级专精特新小巨人企业等。","serverTime":1731698393613,"listedPrice":22.53,"stockholders":"6479人(较上一季度减少13.77%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药康生物(688046)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药康生物,688046,药康生物股票,药康生物股票老虎,药康生物股票老虎国际,药康生物行情,药康生物股票行情,药康生物股价,药康生物股市,药康生物股票价格,药康生物股票交易,药康生物股票购买,药康生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药康生物(688046)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}